Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer-Reference-Cited by-同舟云学术

Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer

Published:2015-12-28 Issue:9 Volume:138 Page:2274-2280
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Nabholtz J.M.¹²³⁴,Chalabi N.¹²³,Radosevic-Robin N.¹⁵,Dauplat M.M.¹⁵,Mouret-Reynier M.A.¹⁴,Van Praagh I.⁴,Servent V.⁶,Jacquin JP⁷,Benmammar K.E.⁴,Kullab S.⁴,Bahadoor M.R.K.⁴⁸,Kwiatkowski F.¹²⁹,Cayre A.¹⁵,Abrial C.¹²³,Durando X.²³⁴¹⁰,Bignon Y.J.¹⁹,Chollet P.²¹¹¹²,Penault-Llorca F.¹⁵

Affiliation:

1. ERTICA EA 4677, University of Auvergne; Clermont-Ferrand France

2. Clinical and Translational Research Division; Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France

3. CIC 501, UMR 766; Clermont-Ferrand France

4. Medical Oncology; Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France

5. Department of Biopathology; Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France

6. Oscar Lambret Comprehensive Cancer Centre; Lille France

7. Lucien Neuwirth Institute; Saint-Etienne France

8. Oncauvergne Regional Oncology Network, Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France

9. LMB GenAuvergne Oncogenetics Department; Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France

10. EA 3846, University of Auvergne; Clermont-Ferrand France

11. Inserm UMR 990; Clermont-Ferrand France

12. University of Auvergne Clermont-Ferrand; Clermont-Ferrand France

Funder

MERCK SERONO and SANOFI-AVENTIS

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference43 articles.

1. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications;Sorlie;Proc Natl Acad Sci USA,2001

2. Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective;Penault-Llorca;Ann Oncol,2012

3. Triple-negative breast cancer: a clinical update;Cleere;Commun Oncol,2010

4. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics;Arteaga;Cancer Cell,2014

5. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype;Cheang;Clin Cancer Res,2008

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Manifestaciones cutáneas asociadas al uso de cetuximab;Piel;2024-05

2. New Biomarkers and Treatment Advances in Triple-Negative Breast Cancer;Diagnostics;2023-06-02

3. Inhibition of ERK signaling for treatment of ERRα positive TNBC;PLOS ONE;2023-05-10

4. Tumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancer;Clinical and Translational Oncology;2022-12-12

5. ‘Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research’;Expert Opinion on Investigational Drugs;2022-12-02